Interferon and TYK2 blockade improve cutaneous lupus activity

This systematic review of randomized trials summarizes efficacy and safety of type I interferon and TNF-alpha targeted agents in cutaneous lupus erythematosus, a topic tangential to routine oncology pharmacy practice but relevant given overlapping biologic and kinase-inhibitor pharmacology.

📅 Journal publication: Jun 30, 2026 · Last updated: Oct 7, 2026

anifrolumabsifalimumabdeucravacitinibBIIB059epratuzumabRSLV-132type I interferon inhibitorsTYK2 inhibitorsTNF-alphacutaneous lupus erythematosussystematic reviewbiologics Rheumatology / Immunology

Background Information

Targeted therapies show promise in cutaneous lupus erythematosus treatment.

Cutaneous lupus erythematosus (CLE) has high symptomatic burden and may not respond to standard treatments, indicating a need for effective alternatives. Targeted therapies against type I interferon (IFN-I) and tyrosine kinase 2 (TYK2) showed efficacy in reducing CLE activity, with anifrolumab showing significant benefits in trials. The study suggests potential benefits of targeted therapy for CLE, although evidence for anti-tumor necrosis factor (TNF) therapies is limited, and some therapies have infection risks. IFN-I blockade is promising for CLE but requires monitoring for infection risks.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Candia González DA, Dávila Vargas D, Arango Machado V, Araque Díaz V, Alzate Granado JP, Gómez Ballesta FJ

Citation: Candia González DA, Dávila Vargas D, Arango Machado V, et al. Targeted therapies against type I interferon and TNF-alpha in cutaneous lupus erythematosus: A systematic review of randomized trials. Dermatology online journal. 2026;32(2). doi:10.25251/mgn4rt3l

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →